STOCK TITAN

Legend Biotech director Peter Salovey buys shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Legend Biotech Corp (LEGN) director Peter Salovey reported direct purchases of 10,000 ordinary shares on November 12, 2026, at $9.3750 per ordinary share, and 10,000 ordinary shares on November 13, 2026, at $8.9500 per ordinary share. The corresponding reported ADS purchase prices were $18.75 and $17.90, respectively; each ADS represents two ordinary shares. No Rule 10b5-1 plan is reported.

Insider Salovey Peter
Role Director
Bought 20,000 shs ($183K)
Increase in Position 36.3%
Type Security Shares Price Value
Purchase Ordinary Shares F1, F3 10,000 $8.95 $90K
Purchase Ordinary Shares F1, F2 10,000 $9.375 $94K
Holdings After Transaction: Ordinary Shares — 75,096 shares (Direct)
Holdings Before and After: Ordinary Shares, 55,096 to 75,096 shares (Direct)
Footnotes (3)
  1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
  2. F2. The price reported in Column 4 represents the converted purchase price of the ADSs of $18.75 per ADS.
  3. F3. The price reported in Column 4 represents the converted purchase price of the ADSs of $17.90 per ADS.
Ordinary shares purchased 10,000 shares Direct purchase on November 12, 2026
Purchase price per ordinary share $9.3750 Direct purchase on November 12, 2026
ADS purchase price $18.75 per ADS Direct purchase on November 12, 2026
Ordinary shares purchased 10,000 shares Direct purchase on November 13, 2026
Purchase price per ordinary share $8.9500 Direct purchase on November 13, 2026
ADS purchase price $17.90 per ADS Direct purchase on November 13, 2026
Ordinary shares per ADS 2 ordinary shares per ADS Each ADS represents two ordinary shares
American Depositary Shares financial
"Each ADS represents two ordinary shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LEGN ordinary shares did director Peter Salovey buy, and at what prices?

Peter Salovey bought 10,000 ordinary shares on November 12, 2026, at $9.3750 per ordinary share, and 10,000 on November 13, 2026, at $8.9500 per ordinary share. The reported ADS purchase prices were $18.75 and $17.90, respectively; each ADS represents two ordinary shares. No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Salovey Peter

(Last)(First)(Middle)
C/O LEGEND BIOTECH CORP
77 CORPORATE DRIVE, 4TH FLOOR

(Street)
BRIDGEWATER NEW JERSEY 08807

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares(1)11/12/2026P10,000A$9.375(2)65,096D
Ordinary Shares(1)11/13/2026P10,000A$8.95(3)75,096D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
2. The price reported in Column 4 represents the converted purchase price of the ADSs of $18.75 per ADS.
3. The price reported in Column 4 represents the converted purchase price of the ADSs of $17.90 per ADS.
/s/ Robert Staloff, Attorney-in-Fact11/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading